Eli Lilly acquires Morphic Holding for $3.2B, focusing on IBD treatment opportunities
Jul 08, 2024•about 1 year ago
Acquiring Company
Eli Lilly and Company
Acquired Company
Morphic Therapeutic
Description
Eli Lilly has purchased Morphic Holding for $3.2 billion, intending to leverage its expertise in the field of gastroenterology. The acquisition is in line with Lilly's commitment to developing new therapies for the benefit of patients, especially in the treatment of inflammatory bowel disease (IBD).
DealWatch™ Score
83
High M&A Activity
M&A Opportunity Analysis
Get personalized insights on M&A opportunities
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed